Naloxone hydrochloride

Name: Naloxone hydrochloride
Brand: MedChemExpress
SKU: HY-17417
Rating: 5.0 (3 reviews)

Cat. No.: HY-17417 Purity: 99.96%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Naloxone hydrochloride is an antagonist of Opioid receptor. Naloxone hydrochloride alleviates opioid-overdose-induced respiratory depression. Naloxone hydrochloride may cause pulmonary edema and cardiac arrhythmias.

For research use only. We do not sell to patients.

Naloxone hydrochloride Chemical Structure

CAS No. : 357-08-4

Size	Price	Stock	Quantity
Free Sample (0.1 - 0.5 mg)		Apply Now
100 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
500 mg	USD 150	In-stock	Estimated Time of Arrival: December 31
1 g		Get quote
5 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Naloxone hydrochloride:

Naloxone-d₅ Get quote
Naloxone Get quote
Naloxone hydrochloride dihydrate Get quote
Naloxone hydrochloride (Standard) Get quote

2 Publications Citing Use of MCE Naloxone hydrochloride

Proliferation Assay

: Naloxone hydrochloride purchased from MedChemExpress. Usage Cited in: Eur J Pain. 2017 May;21(5):804-814. [Abstract]; The SCS1 (early SCS)-mediated increase in the ipsilateral:contralateral PWT ratio (compared to pre-SCS) is significantly reduced by the opioid receptor antagonist, Naloxone, which is administered 10 min before SCS1.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Opioid Receptor Isoform Specific Products:

View All Isoforms

μ Opioid Receptor/MOR κ Opioid Receptor/KOR δ Opioid Receptor/DOR NOP Receptor/ORL1

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

In Vivo

Naloxone (2.0 mg/kg with constant infusion of 1.7 mg/kg/h) causes a significant improvement in neurobehavioral outcome which persists up to 4 weeks postinjury in rat. Naloxone treatment causes a modest and nonsignificant increase in mean arterial blood pressure (MAP)^[1]. Naloxone (0.4 mg/kg) causes memory facilitation and antagonizes the amnestic effect of ACTH and epinephrine in rat^[2]. Naloxone treatment diminishes the strength of the initial tetanus in a dose-related manner in cats. Naloxone (5 or 10 mg/kg, i.v.) causes subsequent doses of morphine to produce less PTP depression but has no effect on maximal twitch depression^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

363.84

Formula

C₁₉H₂₂ClNO₄

CAS No.

357-08-4

Appearance

Solid

Color

White to off-white

SMILES

OC1=C(O2)C([C@]([C@]2([H])C(CC3)=O)(CCN4CC=C)[C@]3(O)[C@H]4C5)=C5C=C1.Cl

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H₂O : 62.5 mg/mL (171.78 mM; Need ultrasonic)

DMSO : ≥ 30 mg/mL (82.45 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7485 mL	13.7423 mL	27.4846 mL
5 mM	0.5497 mL	2.7485 mL	5.4969 mL
10 mM	0.2748 mL	1.3742 mL	2.7485 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

The following protocol is derived from the literature and is for reference only. It is recommended to first try a small sample.

Protocol 1

Naloxone is made up in a vehicle of 2% dimethylformamide (aqueous)^[4].

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.96%

Select Batch:

Data Sheet (286 KB) SDS (393 KB)

COA (261 KB) HNMR (262 KB) RP-HPLC (283 KB) MS (69 KB)

Handling Instructions (2659 KB)

References

[1]. McIntosh TK, et al. Beneficial effect of the nonselective opiate antagonist naloxone hydrochloride and the thyrotropin-releasing hormone (TRH) analog YM-14673 on long-term neurobehavioral outcome following experimental brain injury in the rat. J Neurotrau [Content Brief]

[2]. Sun L, et al. Endocannabinoid activation of CB1 receptors contributes to long-lasting reversal of neuropathic pain by repetitive spinal cord stimulation. Eur J Pain. 2017 May;21(5):804-814. [Content Brief]

[3]. Izquierdo I, et al. Effect of ACTH, epinephrine, beta-endorphin, naloxone, and of the combination of naloxone or beta-endorphinwith ACTH or epinephrine on memory consolidation. Psychoneuroendocrinology. 1983;8(1):81-7. [Content Brief]

[4]. Soteropoulos GC, et al. Neuromuscular effects of morphine and naloxone. J Pharmacol Exp Ther. 1973 Jan;184(1):136-42. [Content Brief]

Animal Administration
^[2]

Young adult Wistar rats are used in the assay: females for experiments l and 3 (age 50-70 days, weight 100-185 g) and males for experiments 2 and 4 (age 51-69 days, weight 140-200 g). The same apparatus is used for both: a 50×25×25 cm box made of plywood with a frontal glass wall, whose floor consists of 1 mm-caliber bronze bars spaced l0 mm apart. In task l, a 5 cm high, 25×25 cm wooden platform is introduced into the box so as to cover the left half of the grid. Rats are held gently by their bodies and loared onto the platform facing the rear left corner, at which time a quartz chronometer is activated. Time is counted until the animals stepped down from the platform and placed their four paws on the grid, upon which a 0.5 mA, 60 Hz footshock is continuously delivered until the animals return to the platform. In task 2 the platform is only 7 cm wide and covered only the leftmost seven bars of the grid; the footshock is of only 0.3 mA and is delivered in 0.4 msec pulses once every 2 sec until the animals climb back onto the platform. Immediately after training in each task the animals are withdrawn from the box injected i.p. with one of the following: saline (1.0 mL/kg), ACTH_1-24 (0.2 or 2.0 μg/kg), epinephrine HCl (5.0 or 50.0 μg/kg), human β-endorphin (0.1 or 1.0 μg/kg), naloxone HCl (0.4 mg/kg), or ACTH or epinephrine given together with either β-endorphin or naloxone. All drugs are dissolved in saline to an injection volume of 1.0 mL/kg. Twenty-four hr after training the animals again are placed on the platform (the wide one for task 1, experiments 1 and 2, and the narrow one for task 2, experiments 3 and 4), and their latency to stepdown onto the grid again is measured as in the training session. A ceiling of 180 sec is imposed on this measure.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. McIntosh TK, et al. Beneficial effect of the nonselective opiate antagonist naloxone hydrochloride and the thyrotropin-releasing hormone (TRH) analog YM-14673 on long-term neurobehavioral outcome following experimental brain injury in the rat. J Neurotrau [Content Brief]

[2]. Sun L, et al. Endocannabinoid activation of CB1 receptors contributes to long-lasting reversal of neuropathic pain by repetitive spinal cord stimulation. Eur J Pain. 2017 May;21(5):804-814. [Content Brief]

[3]. Izquierdo I, et al. Effect of ACTH, epinephrine, beta-endorphin, naloxone, and of the combination of naloxone or beta-endorphinwith ACTH or epinephrine on memory consolidation. Psychoneuroendocrinology. 1983;8(1):81-7. [Content Brief]

[4]. Soteropoulos GC, et al. Neuromuscular effects of morphine and naloxone. J Pharmacol Exp Ther. 1973 Jan;184(1):136-42. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / H₂O	1 mM	2.7485 mL	13.7423 mL	27.4846 mL	68.7115 mL
	5 mM	0.5497 mL	2.7485 mL	5.4969 mL	13.7423 mL
	10 mM	0.2748 mL	1.3742 mL	2.7485 mL	6.8712 mL
	15 mM	0.1832 mL	0.9162 mL	1.8323 mL	4.5808 mL
	20 mM	0.1374 mL	0.6871 mL	1.3742 mL	3.4356 mL
	25 mM	0.1099 mL	0.5497 mL	1.0994 mL	2.7485 mL
	30 mM	0.0916 mL	0.4581 mL	0.9162 mL	2.2904 mL
	40 mM	0.0687 mL	0.3436 mL	0.6871 mL	1.7178 mL
	50 mM	0.0550 mL	0.2748 mL	0.5497 mL	1.3742 mL
	60 mM	0.0458 mL	0.2290 mL	0.4581 mL	1.1452 mL
	80 mM	0.0344 mL	0.1718 mL	0.3436 mL	0.8589 mL
H₂O	100 mM	0.0275 mL	0.1374 mL	0.2748 mL	0.6871 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.